Search
Research
Transiently increased IgE responses in infants and pre-schoolers receiving only (DTaP) vaccines compared to those initially receiving at least one dose of DTwP vaccineConfirm the generalised IgE-trophic activity of the DTaP vaccine in pre-schoolers and demonstrate similar (albeit transient) effects in infants
Research
Secondary preventive medication use in a prevalent population-based cohort of acute coronary syndrome survivorsLonger time since last acute coronary syndrome admission was associated with dispensing fewer medications types and combinations in 2008
Research
Adherence to secondary prophylaxis for rheumatic heart disease is underestimated by register data.Adequate resources are needed for maintenance of data quality in acute rheumatic fever/ rheumatic heart disease registers to ensure provision of evidence-based care and accurate assessment of program impact.
Research
Improving delivery of secondary prophylaxis for rheumatic heart disease in remote Indigenous communitiesThis trial aims to improve uptake of secondary prophylaxis among Aboriginal people with ARF/RHD to reduce progression or worsening of RHD.
Research
Structured review of primary interventions to reduce group A streptococcal infections, acute rheumatic fever and rheumatic heart diseaseRheumatic heart disease (RHD) is a large, preventable, global public health burden. In New Zealand (NZ), acute rheumatic fever (ARF) and RHD rates are highest for Māori and Pacific children. This structured review explores the evidence for primary prevention interventions to diagnose and effectively treat group A Streptococcus (GAS) pharyngitis and skin infections to reduce rates of ARF and RHD.
Research
Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection studyWe review the Group A Streptococcus Human infection studies and present the study protocol for a dose-ranging inpatient study in healthy adults
Research
An economic case for a vaccine to prevent group A streptococcus skin infectionsA vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability
Research
Primary prevention of rheumatic fever in the 21st century: evaluation of a national programmePopulation-based primary prevention of ARF through sore throat management may be effective in well-resourced settings like New Zealand
Research
Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveysDirect and indirect effects on pneumococcal carriage post-PCV10 are likely to result in reductions in pneumococcal disease, including in infants too young to be vaccinated
Research
Call for a national sore throat guidelineAustralia needs a single national pharyngitis guideline to assist in providing rational, consistent and timely antibiotic treatment to patients at high risk of ARF